- Home
- »
- Pharmaceuticals
- »
-
Biomarkers Market Size, Share & Trends Report, 2026-2033GVR Report cover
Biomarkers Market (2026 - 2033)
Size, Share & Trends Analysis Report By Type (Efficacy, Validation, Prognostics, Pharmacodynamic), By Type, By Application (Drug Discovery & Development, Personalized Medicine), By Disease, By Region, And Segment Forecasts
Market Size, 2025
$98.3BMarket Estimate, 2026
$111.9BMarket Forecast, 2033
$279.3BCAGR, 2026–2033
14.0%Biomarkers Market Summary
The global biomarkers market size was valued at USD 98.3 billion in 2025 and is projected to grow from USD 111.9 billion in 2026 to USD 279.3 million by 2033, at a CAGR of 14.0% from 2026 to 2033. North America market dominated, with a revenue share of 44.1% in 2025. The rising prevalence of cancer, significance of companion diagnostics, investments in research, and significant innovations owing to ongoing research are anticipated to drive market growth.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By type: Safety segment led the market with the largest revenue share of 37.4% in 2025.
- By application: Drug discovery & development segment led the market with the largest revenue share of 31.7% in 2025.
- By disease: Cancer segment led the market with the largest revenue share of 36.7% in 2025.
Regional Highlights
- Largest regional market: North America (44.1% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market size in 2025: USD 98.3 Billion
- Estimated market size in 2026: USD 111.9 Billion
- Projected market size by 2033: USD 279.3 Billion
- CAGR (2026-2033): 14.0%
Three ways to get this report
Buy it, customize it, or ask a question.Ask an Analyst
Analyst response in 1 business day
- AccessReport author, directly
- Reply timeWithin 1 working day
- No sales callDirect answer only
- FormatEmail reply
- CostFree, no cost
Get the Full Report
What the study covers
- FormatsPDF · Excel · Dashboard
- Timeline2026–2033 annual, 2025 base
- Coverage20+ countries, 5 regions
- Companies10+ key players profiled
Customize the Report
20% free customization
- IncludeCountries, segments, points
- TailorTo your product definition
- ExtendDeeper competitor detail
- OrA fully bespoke study
- Turnaround5–10 working days
For instance, in February 2023, National Institutes of Health announced funding of USD 4 million to Eastern Virginia Medical School (EVMS) for research and development of biomarker for early detection of aggressive prostate cancer.Increase in the prevalence of fatal diseases has been observed over the past few years, which includes cancer, diabetes, cardiovascular disorders, and other chronic diseases. One of the major factors leading to an increase in their prevalence is lifestyle changes. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases are expected to be registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. According to the World Health Organization (WHO), in 2022, an estimated 236,740 new cases of lung cancer were expected to be reported in the U.S., accounting for 130,180 deaths.
To learn more about this report, Download Free Sample Report The use of biomarkers in infectious disease diagnosis is anticipated to become increasingly common in the upcoming years. For instance, as per Frontiers in Microbiology in 2020 , potential MicroRNA-based biomarkers have been identified for the diagnosis of infections such as influenza infections, rhinoviruses, HIV, tuberculosis, malaria, Ebola, and Hendra virus. These are aimed at facilitating early onset of infectious diseases. Biomarkers are also under study for the diagnosis of SARS-CoV-2. They have a high prognostic potential, which is projected to play a crucial role in the diagnosis of asymptomatic cases that hinder the tracking of pandemic cases. Furthermore, the high stability despite freeze and thaw cycles gives them an added advantage.
Innovative treatments that combine biomarkers with new or existing medicines are continuously being launched. For instance, biomarkers can now be used for the treatment of neurological diseases to track brain health by measuring molecules. Recent developments are making treatment of neurological diseases easier, for example, the development of biomarker signatures. This has resulted in noninvasive testing, faster drug development, and early diagnosis. R&D is leading to the discovery of novel biomarkers.
The emergence of digital biomarker which assists pharmaceutical companies with contextual and supplementary information to conclude clinical trial decisions is further propelling growth of the market. IXICO plc, a digital technology-based company that has expertise in neurosciences, is collaborating with biopharmaceutical companies to validate clinically digital biomarkers and use them in regulatory compliant clinical trials. Another new biomarker technology published in PLOS Journal in June 2021 is bowel cancer relapse detection biomarkers with the help of ctDNA. This can be used as a prognostic tool that predicts the recurrence with a 100% accuracy rate, thereby enabling better treatment.
Leading players are focusing on introducing programs that can increase the commercialization of biomarker-based products. For instance, in November 2022, NeoGenomics, under the sponsorship of ImmunoGen, launched a novel biomarker testing program for patients with Epithelial Ovarian Cancer (EOC). This initiative targeted FRα in patients with platinum-resistant EOC and increased patient access to FDA-approved ImmunoGen's ADC, ELAHERE. Similarly, in April 2021, Amgen launched a Biomarker Assist Program for metastatic Non-Small Cell Lung Cancer (NSCLC) patients and increased access to testing.
Market Dynamics
The biomarker market is expanding due to the growing adoption of precision medicine, increasing demand for early disease detection, and broader integration of molecular and protein biomarkers across drug development and clinical diagnostics. Pharmaceutical and biotechnology companies are increasingly incorporating biomarker-based approaches to improve patient selection, enhance clinical trial success rates, and support targeted therapy development. Healthcare providers are also adopting biomarker testing to enable personalized treatment decisions and improve disease monitoring across oncology, neurology, cardiovascular, and infectious diseases. Continuous advances in genomics, proteomics, and artificial intelligence are improving biomarker discovery and validation, supporting wider commercialization. A recent industry development highlights this trend. For instance, in 2025, Quanterix Corporation announced its merger with Akoya Biosciences to combine ultra-sensitive blood based biomarker detection with spatial biology technologies, strengthening integrated biomarker research capabilities and accelerating translational medicine applications. The growing collaboration between diagnostic companies, research organizations, and pharmaceutical developers is expected to support continued innovation and expand the use of biomarkers across clinical practice and therapeutic development.
The growing adoption of precision medicine is a primary driver of the biomarker market as healthcare systems increasingly emphasize personalized treatment approaches over conventional therapies. Biomarkers enable clinicians to identify disease specific biological characteristics, predict treatment response, and monitor patient outcomes with greater accuracy. Pharmaceutical companies are also expanding biomarker integration throughout drug discovery and clinical development to improve trial efficiency and support regulatory approvals for targeted therapies. Increasing investments in genomic research, companion diagnostics, and molecular profiling continue to strengthen demand across oncology, neurology, cardiovascular diseases, and rare disorders. For instance, in November 2025, Servier India partnered with MedGenome and Strand Life Sciences to launch a patient centric biomarker testing initiative for Acute Myeloid Leukemia and Cholangiocarcinoma. The collaboration expanded access to IDH1 and IDH2 mutation testing across public and private healthcare settings, supporting precision oncology and wider adoption of biomarker guided treatment.The biomarker market faces restraints due to the complexity of biomarker discovery, clinical validation, and regulatory standardization across different healthcare systems. Demonstrating consistent analytical performance and clinical utility requires extensive validation studies, increasing development costs and extending commercialization timelines. Variations in laboratory procedures, sample quality, and testing methodologies can also affect the reproducibility of biomarker results, limiting broader clinical adoption. In addition, reimbursement challenges for novel biomarker assays in several countries continue to slow their integration into routine healthcare practice. The evolving regulatory environment also requires developers to generate stronger clinical evidence and standardized validation data before new biomarker technologies can achieve widespread clinical adoption and commercial acceptance.The increasing integration of artificial intelligence with biomarker discovery and clinical research presents a significant opportunity for the biomarker market. AI powered data analysis enables researchers to process large scale genomic, proteomic, and clinical datasets more efficiently, accelerating the identification and validation of novel biomarkers. This capability supports faster drug development, improves patient stratification, and enhances the design of precision medicine strategies. Growing collaborations between pharmaceutical companies, biotechnology firms, and AI developers are further strengthening innovation in biomarker based diagnostics and therapeutic development. For instance, in May 2026, Roche signed a definitive agreement to acquire PathAI to strengthen its artificial intelligence driven digital pathology portfolio and enhance biomarker discovery and companion diagnostics capabilities. The integration of AI with digital pathology and molecular diagnostics is expected to create new opportunities for precision medicine and improve the development of biomarker based clinical solutions.Market Concentration & Characteristics
Market growth stage is high and the pace is accelerating. The biomarkers market is characterized by a high degree of innovation fueled by rapid technological advancements. R&D is leading to the discovery of novel biomarkers. For instance, as per Nature Journal in 2020 , tetranectin is a potential biomarker for heart failure diagnosis. Similarly, in 2020, sTNFR2 was revealed as a novel biomarker for the diagnosis of acute adult T-cell leukemia/lymphoma. The market is likely to witness lucrative growth over the forecast period due to such discoveries and technological advancements.
To learn more about this report, Download Free Sample Report The industry is also characterized by a high level of partnership and collaboration activity by the leading players. It is one of the most adopted strategies by the players to enhance early commercialization of their products and improve the availability of products. For instance, in March 2023, Koneksa extended its partnership with SSI Strategy to scale and accelerate the adoption of digital biomarkers.
The biomarker segment is witnessing rapid technological advancements and high demand for personalized medicine. Thus, to ensure patient access to these new technologies, a reimbursement framework needs to be worked upon to meet the changing market scenario. This will potentially encourage manufacturers to invest in new products as reimbursement policies have a direct impact on the development and growth of diagnostic & prognostic tools.
The market players undertake this strategy to strengthen their product portfolios and offer diverse technologically advanced & innovative products to their customers. This is the most prominently adopted strategy by the companies to attract more customers. For instance, in July 2022, the U.S. FDA granted Breakthrough Device Designation to Elecsys Amyloid Plasma Panel for early detection of Alzheimer’s disease. Roche is the first IVD manufacturer to receive Breakthrough Device Designation for a blood-based biomarker test for Alzheimer’s.
Analyst Perspective
The biomarker market is positioned for sustained growth, driven by the increasing adoption of precision medicine, expanding applications of companion diagnostics, and continuous advancements in genomics, proteomics, and artificial intelligence. Growing pharmaceutical investments in biomarker guided drug development and increasing demand for early disease detection are accelerating market expansion across oncology, cardiovascular, neurological, and immunological diseases. Regulatory support for personalized therapies and the integration of multiomics technologies are further strengthening innovation. Strategic collaborations between diagnostic companies, biotechnology firms, and pharmaceutical manufacturers are expected to enhance biomarker discovery, validation, and commercialization, creating opportunities for improved clinical decision making and more targeted therapeutic development.
Type Insights
Based on type, the Safety segment led the market with the largest revenue share of 37.4% in 2025. Safety biomarkers can be used to customize therapies for patients, due to high risk of adverse reactions. They can predict or detect exposure effects or adverse drug events. Increase in the use of safety biomarkers in drug discovery & development is anticipated to boost market growth.Furthermore, an increase in population at high risk of developing various diseases, such as cancer, cardiovascular conditions, and kidney disorders, is expected to positively influence the market. Growing awareness of routine health checkups and lower drug attrition rates, which have been linked to biomarker-based therapies, are driving segment growth.
To learn more about this report, Download Free Sample Report The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030. Efficacy biomarkers aid in predicting patient responses to a specific drug. Despite the challenges in research, several findings have been reported on efficacy biomarkers. For instance, ATPase-copper Transporting β Polypeptide (ATP7B) is a biomarker used for detection of ovarian cancer. Furthermore, collaborative efforts between companies and academic institutes are expected to enhance the discovery of biomarkers. For instance, in June 2023, the National Cancer Institute announced the launch of ComboMatch platform trial which helps researchers to test efficacy of treatment combinations.
Product Insights
The consumables segment led the market in 2023. The growing emphasis on personalized and precision medicine has led to a growing need for biomarkers to identify specific disease markers and tailor treatment plans accordingly. This drives the demand for consumables used in biomarker discovery and validation. Moreover, the rising prevalence of chronic diseases such as cardiovascular diseases, cancer, and neurodegenerative disorders have led to an increase in consumption of consumables further driving market growth.
The services segment is anticipated to exhibit a lucrative CAGR over the projected period. Biomarkers are used in clinical trials for patient stratification, monitoring treatment responses, and assessing safety. Biomarker services support the design, implementation, and analysis of clinical trials, ensuring that biomarkers are effectively utilized for decision-making in drug development. Moreover, clinical laboratories and diagnostic service providers offer biomarker-based diagnostic testing services for various diseases. These services help in the accurate and reliable detection of biomarkers, contributing to early disease diagnosis and monitoring.
Application Insights
Based on application, the drug discovery & development segment led the market with the largest revenue share of 31.7% in 2025. Biomarkers can be beneficial for accelerating drug development for certain diseases by predicting drug efficacy more easily than conventional clinical endpoints. Hence, they can help in identifying candidates that are likely to fail, thereby reducing drug development costs. Therefore, key players operating in this segment are focused on using biomarkers in drug development, which is leading to strategic alliances and thus driving the market.For instance, in June 2022, InterVenn Biosciences collaborated with the Foundation for the National Institutes of Health’s Biomarker Consortium and the Worldwide Innovative Network (WIN) Consortium, which aims to advance clinical trials, improve patient care, enhance precision oncology, and accelerate biomarker discovery.
The diagnostics segment is projected to register the fastest CAGR from 2024 to 2030. The increasing research focused on identification of new diagnostic biomarkers is fueling this growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma. These can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers.R&D in the segment confirms the development of novel biomarkers for early-stage detection of diseases such as Alzheimer's.
Disease Insights
Based on disease, the Cancer segment led the market with the largest revenue share of 36.7% in 2025. The growth of this segment is attributed to an increase in demand for rapid & accurate diagnostic tools and rise in global incidence of cancer. According to Global Cancer Observatory, about 19.3 million new cancer cases were recorded in 2020, while around 10 million cancer deaths were reported in the same year. In addition, growth in research activities for discovery and development of novel cancer biomarkers is widening the scope for market growth. In June 2022, researchers from the Tokyo University of Agriculture and Technology developed a novel technique based on DNA computation for the identification of cancer miRNA patterns. By using low concentrations of the target biomarkers, the new technique can be a promising tool for early cancer diagnosis.
The immunological diseases segment is expected to attain the fastest CAGR from 2024 to 2030. This is mainly attributed to the increase in research aided with the rising prevalence of immunological diseases. For instance, in May 2023, according to article published by Boston Children’s Hospital, researchers have identified immune biomarkers that have helped in predicting COVID-19 severity and are mostly likely to help in future pandemics.Furthermore, increasing R&D in the renal biomarkers segment is anticipated to fuel the segment’s growth. For instance, in May 2022, researchers from the University of Houston, with the help of immunoproteomics-based discovery studies, reported potential biomarkers related to lupus nephritis related to clinical parameters, such as renal pathology indices. These biomarkers for lupus nephritis can be used to provide more reliable clinical blood tests for the disease, replacing kidney biopsy, which is a currently used invasive test.
Regional Insights
North America dominated the Biomarkers Market with the largest revenue share of 44.1% in 2025, due to high disease burden, technological advancements, increased consumer awareness, supportive government initiatives, and improvements in healthcare infrastructure. Local presence of key players is anticipated to increase the penetration of novel biomarkers. Major players operating in the market include Abbott; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc.; and Bio-Rad Laboratories, Inc.; Many academic institutions, research centers, and universities are collaborating with key market players to develop biomarkers for diagnosing and monitoring numerous diseases. Increasing efforts for the development of digital biomarkers and increasing investments as well as collaboration activities are anticipated to drive growth.
To learn more about this report, Download Free Sample Report U.S. Biomarkers Market Trends
The Biomarkers Market in the U.S. held the largest share in the North America region in 2025.
Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030. Factors such as high prevalence of cancer, surge in funding for discovery, low cost of clinical trials in developing nations, and rising research initiatives are expected to support regional growth. Several advancements in R&D by biopharmaceutical companies are expected to positively impact the market. For instance, in December 2021, Denovo Biopharma LLC announced the discovery of a novel genetic marker for a gene therapy-based medicine. This would facilitate treatment for patients with recurrent high-grade glioma, an unmet medical need with estimated survival of less than a year.
Key Companies & Market Share Insights
Some of the leading market players include F. Hoffmann-La Roche AG, Abbott, QIAGEN, and PerkinElmer Incorporated. Key players are focusing on geographic expansions and gaining market approvals for innovative products. These players are heavily investing in advanced technology and infrastructure, allowing them to efficiently process & analyze a large volume of samples. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their market presence.
Atlas Genetics Ltd.; Hologic, Inc.;Myriad Genetics, Inc.; and Genomic Health, Inc. are some of the emerging market participants. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel product launches to capitalize on untapped avenues.
Key Biomarkers Companies:
The following key companies have been profiled for this study on the biomarkers Market
- F. Hoffmann-La Roche AG
- Epigenomics AG
- Abbott
- Thermo Fisher Scientific Inc
- General Electric
- Eurofins Scientific
- Johnson & Johnson Services, Inc.
- QIAGEN
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- Merck KGaA
- PerkinElmer Inc.
- Agilent Technologies, Inc.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Well Established Players (F. Hoffmann-La Roche AG, Abbott, Thermo Fisher Scientific Inc., QIAGEN, Siemens Healthineers AG, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Eurofins Scientific)
- Focus on expanding comprehensive biomarker portfolios through genomic, proteomic, molecular, and companion diagnostic technologies for oncology, cardiovascular, neurological, and immunological diseases. These companies emphasize strategic acquisitions, regulatory approvals, geographic expansion, laboratory automation, artificial intelligence integration, and partnerships with pharmaceutical companies to strengthen biomarker discovery and precision medicine capabilities.
- Strong global brand recognition, broad diagnostic and life science portfolios, extensive regulatory expertise, well established relationships with pharmaceutical companies, research institutions, and healthcare providers, and significant investments in research and development. Their integrated platforms enable end to end biomarker discovery, validation, clinical testing, and companion diagnostic solutions.
- Large organizational structures can delay technology commercialization and product customization. Dependence on extensive regulatory approvals, premium pricing, and complex product portfolios may reduce flexibility in addressing niche biomarker applications or the evolving needs of smaller research organizations and biotechnology companies.
Emerging Players (Epigenomics AG, General Electric, Johnson & Johnson Services, Inc., Atlas Genetics Ltd., Hologic, Inc., Myriad Genetics, Inc., Genomic Health, Inc.)
- Concentrate on developing specialized biomarker technologies including liquid biopsy, epigenetic biomarkers, molecular diagnostics, and disease specific companion diagnostics. Their strategies include securing government funding, launching innovative products, collaborating with academic institutes, pharmaceutical companies, and healthcare organizations, and expanding into underserved precision medicine applications.
- Greater specialization enables rapid innovation, faster adoption of emerging biomarker technologies, and stronger focus on disease specific applications. These companies maintain flexibility in product development and collaborate closely with research organizations to accelerate biomarker discovery and clinical translation.
- Limited commercial scale, lower brand recognition, restricted global distribution networks, and comparatively smaller research budgets may constrain market expansion. They may also face challenges in obtaining broad regulatory approvals, scaling manufacturing, and competing with diversified multinational diagnostics companies.
Recent Developments
-
In October 2023, Labcorp announced the launch of tri-biomarkers blood test for diagnosis of Alzheimer’s disease.
-
In October 2023, Mindray announced the launch of high-sensitivity NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers. The launch is expected to enhance the company’s product portfolio of cardiac biomarkers used in the management and diagnosis of cardiovascular diseases.
-
In August 2023 , Quest Diagnostics entered into partnership with Envision Sciences for the commercial launch of novel prostate cancer biomarker test for identification of severe and aggressive forms of the disease.
-
In February 2023, Cardio Diagnostics Holdings Inc. announced the launch of PrecisionCHD, a epigenetic-genetic blood test for early diagnosis of coronary heart disease.
Biomarkers Market Report Scope
Report Attribute
Details
Market size in 2025
USD 98.3 billion
Estimated market size in 2026
USD 111.9 billion
Projected market size by 2033
USD 279.3 billion
Growth rate
CAGR of 14.0% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Type, Application, Disease Regional
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; and Kuwait
Key companies profiled
F. Hoffmann-La Roche AG, Epigenomics AG, Abbott, Thermo Fisher Scientific Inc., General Electric, Eurofins Scientific, Johnson & Johnson Services, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Siemens Healthineers AG, Merck KGaA, PerkinElmer Inc., and Agilent Technologies, Inc.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Biomarkers Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the biomarkers market report based on type, product, application, disease, and region:
-
Type Outlook (Revenue, USD Million, 2021 - 2033)
-
Safety Biomarkers
-
Efficacy Biomarkers
-
Predictive Biomarkers
-
Surrogate Biomarkers
-
Pharmacodynamic Biomarkers
-
Prognostics Biomarkers
-
Validation Biomarkers
-
-
Product Outlook (Revenue, USD Million, 2021 - 2033)
-
Consumable
-
Services
-
Software
-
-
Application Outlook (Revenue, USD Million, 2021 - 2033)
-
Diagnostics
-
Drug Discovery & Development
-
Personalized Medicine
-
Disease Risk Assessment
-
Others
-
-
Disease Outlook (Revenue, USD Million, 2021 - 2033)
-
Cancer
-
Safety Biomarkers
-
Efficacy Biomarkers
-
Predictive Biomarkers
-
Surrogate Biomarkers
-
Pharmacodynamic Biomarkers
-
Prognostics Biomarkers
-
Validation Biomarkers
-
-
Cardiovascular Diseases
-
Safety Biomarkers
-
Efficacy Biomarkers
-
Predictive Biomarkers
-
Surrogate Biomarkers
-
Pharmacodynamic Biomarkers
-
Prognostics Biomarkers
-
Validation Biomarkers
-
-
Neurological Diseases
-
Safety Biomarkers
-
Efficacy Biomarkers
-
Predictive Biomarkers
-
Surrogate Biomarkers
-
Pharmacodynamic Biomarkers
-
Prognostics Biomarkers
-
Validation Biomarkers
-
-
Immunological Diseases
-
Safety Biomarkers
-
Efficacy Biomarkers
-
Predictive Biomarkers
-
Surrogate Biomarkers
-
Pharmacodynamic Biomarkers
-
Prognostics Biomarkers
-
Validation Biomarkers
-
-
Others
-
Safety Biomarkers
-
Efficacy Biomarkers
-
Predictive Biomarkers
-
Surrogate Biomarkers
-
Pharmacodynamic Biomarkers
-
Prognostics Biomarkers
-
Validation Biomarkers
-
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The biomarkers market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each biomarkers segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Type
Revenue capture definition
Safety Biomarkers
Revenue is primarily captured from biomarker assays, analytical platforms, and related services used to evaluate drug safety, detect toxicity, monitor adverse biological responses, and support preclinical and clinical safety assessments during therapeutic development.
Efficacy Biomarkers
Revenue flows from biomarker products and testing services used to measure therapeutic response, monitor treatment effectiveness, assess disease progression, and support patient stratification in clinical trials and routine clinical practice.
Validation Biomarkers
Market value is captured through biomarker validation assays, laboratory services, analytical software, and regulatory support solutions used to confirm biomarker accuracy, reproducibility, clinical relevance, and fitness for research or clinical applications.
Segment - Application
Revenue capture definition
Diagnostics
Revenue is primarily captured from biomarker assays, diagnostic kits, analytical instruments, and laboratory testing services used for disease detection, diagnosis, prognosis, treatment selection, and patient monitoring across clinical settings.
Drug Discovery & Development
Revenue flows from biomarker platforms, research assays, analytical technologies, and contract research services used to identify drug targets, support preclinical studies, optimize clinical trials, and improve therapeutic development outcomes.
Personalized Medicine
Market value is derived from biomarker tests, companion diagnostics, genomic profiling solutions, and related clinical services that enable patient stratification, targeted therapy selection, and individualized treatment planning.
Others
Revenue is captured from biomarker applications in disease risk assessment, health monitoring, forensic analysis, agricultural research, environmental studies, and academic research that fall outside core diagnostic and therapeutic development applications.
Segment - Disease
Revenue capture definition
Cancer
Revenue is primarily captured from biomarker assays, companion diagnostics, molecular profiling tests, and related laboratory services used for cancer detection, prognosis, therapy selection, treatment monitoring, and recurrence assessment.
Cardiovascular Diseases
Revenue flows from biomarker tests, immunoassays, diagnostic analyzers, and laboratory services used to detect cardiac injury, assess cardiovascular risk, monitor disease progression, and guide treatment decisions.
Neurological Diseases
Market value is derived from biomarker assays, molecular diagnostics, imaging biomarkers, and laboratory testing services used for the diagnosis, prognosis, and monitoring of neurodegenerative and neurological disorders.
Immunological Diseases
Revenue is obtained from biomarker testing solutions, immunoassays, multiplex assays, and laboratory services used to diagnose autoimmune disorders, monitor immune responses, and evaluate disease activity and treatment effectiveness.
Others
Revenue is captured from biomarker products and testing services used across infectious diseases, metabolic disorders, respiratory diseases, rare diseases, renal disorders, and other clinical applications beyond the primary disease categories.
Estimation Model
To learn more about this report, Download Free Sample Report The biomarker market size was estimated using a bottom up approach by identifying key manufacturers, benchmarking their biomarker products and estimating revenues generated across major biomarker technologies and applications. Market estimates were validated using technology adoption trends, disease specific utilization rates, and the market share of leading companies to derive the overall market size.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Biomarker Competitive Landscape & Technology Assessment
Assessed the global biomarker ecosystem across diagnostic companies, life science tool providers, pharmaceutical companies, CROs, research institutes, and biotechnology firms. Evaluated genomic, proteomic, metabolomic, transcriptomic, epigenetic, and digital biomarkers, along with companion diagnostics, liquid biopsy technologies, and biomarker discovery platforms across major therapeutic areas.
Enabled benchmarking of leading and emerging market participants, identified innovation opportunities across multiomics and precision medicine, evaluated competitive positioning in biomarker discovery and clinical diagnostics, and highlighted technology adoption trends supporting personalized healthcare and drug development.
Biomarker Regulatory, Clinical Validation, Commercialization & Market Access
Analyzed regulatory frameworks, biomarker qualification pathways, clinical validation requirements, reimbursement trends, companion diagnostic approvals, laboratory accreditation standards, and commercialization strategies across major healthcare markets. Assessed challenges related to analytical validation, clinical utility, and integration into routine clinical practice.
Supported regulatory and commercialization planning, identified reimbursement and adoption barriers, evaluated validation requirements for biomarker-based diagnostics, and provided strategic guidance for market entry, product approval, clinical implementation, and global commercialization.
Comprehensive Biomarker Innovation & Precision Medicine Technology Assessment
Evaluated advancements in artificial intelligence driven biomarker discovery, multiomics integration, spatial biology, liquid biopsy, next generation sequencing, proteomics, digital pathology, and cloud-based biomarker analytics. Assessed emerging applications across oncology, cardiovascular, neurological, immunological, and rare diseases.
Highlighted high growth innovation areas, identified technologies accelerating biomarker discovery and precision medicine, assessed opportunities for companion diagnostics and targeted therapies, and provided competitive insights into future technology adoption and clinical translation.
Frequently Asked Questions About This Report
The global biomarkers market size was valued at USD 81.0 billion in 2023 and is estimated at USD 117.1 billion for 2026.
Cancer dominated the disease segment in 2023 with 37.45% of the market share, driven by a heightened demand for accurate and rapid diagnostic tools as well as a sharp growth in prevalence on a global scale.
Some key players operating in the biomarkers market include Abbott; Qiagen; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific, Inc.; Siemens Healthineers AG; Bio-Rad Laboratories, Inc.; Johnson & Johnson Services, Inc; and Epigenomics AG.
The global biomarkers market is expected to grow at a CAGR of 13.4% from 2024 to 2030, reaching USD 194.2 billion by 2030.
The increasing prevalence of chronic diseases, advancements in the techniques used for the development of biomarker-based diagnostics, and the growing geriatric population are factors likely to boost the biomarkers market significantly throughout the forecast period.
About the Author(s)
Pharmaceuticals Research Team
Healthcare · PharmaceuticalsThis report was authored by the pharmaceuticals research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the pharmaceuticals segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
